8 November 2022FeaturesMuireann Bolger

Sea change: a Q&A with Kathi Vidal

You have always been a proponent of diversity and inclusion. What drove you to make that an area of focus?

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Biotech

Interview: How BlueRock Therapeutics is layering IP in stem cell therapies

13 July 2026 The company’s VP of IP explains how he is protecting the process, staying ahead of outside counsel, and why a biosimilar path is only a matter of time.

Americas

Explaining genetically engineered rodents to a jury—and ultimately beating Amgen

10 July 2026 Harbour’s trial counsel shares the strategy behind the company’s $20m win, revealing how a highly technical patent dispute became a case about credibility as much as science.

Americas

Exelixis opens two-front patent dispute over Cabometyx copies

9 July 2026 Separate lawsuits target Indian and Taiwanese pharma companies as Exelixis seeks to keep rival cabozantinib products off the US market until key patents expire.

More features

Exclusive: ‘Cultural differences are an asset’ at the UPC

WATCH: AI-powered patent prosecution for life sciences innovation

WATCH: Overcoming patent eligibility, patentability, and disclosure requirements in life sciences innovation

Five generations at work: How teams are bridging the gap

Squires refuses to resurrect HydraFacial patent review

Patent office fee increases: What applicants must know

LSPN Awards USA: Meet the judges

Closing the women's health gap offers ‘benefits for all’

Sea change: a Q&A with Kathi Vidal

More on this story

Editor's picks

Editor's picks

More features